NOVN.CH

117.3

-0.46%↓

SOON.CH

204.4

-1.83%↓

NOVN.CH

117.3

-0.46%↓

SOON.CH

204.4

-1.83%↓

NOVN.CH

117.3

-0.46%↓

SOON.CH

204.4

-1.83%↓

NOVN.CH

117.3

-0.46%↓

SOON.CH

204.4

-1.83%↓

NOVN.CH

117.3

-0.46%↓

SOON.CH

204.4

-1.83%↓

Home・Aandelen Lijst・Roche Holding AG

Roche Holding AG

Open

SectorGezondheidszorg

330.2 -0.54

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

329.8

Max

333

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8B 5.5B
Verkoop	15B 31B
K/W Sectorgemiddelde	19.838 49.888
Dividendrendement	3.02
Winstmarge	17.892
Werknemers	103,249
EBITDA	5.1B 12B

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	3.02% 2.38%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-36B 253B
Vorige openingsprijs	330.74
Vorige sluitingsprijs	330.2

Nieuwssentiment

By Acuity

16%

84%

17 / 344 Rangschikking in Healthcare

Roche Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 06:06 UTC

Acquisities, Fusies, Overnames

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

23 apr 2026, 07:46 UTC

Winsten

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 apr 2026, 05:40 UTC

Winsten

Roche Backs Full-Year View as Quarterly Sales Rise

9 mrt 2026, 16:43 UTC

Belangrijke Marktbewegers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mrt 2026, 15:44 UTC

Belangrijke Marktbewegers

Correction to Roche Shares Article

9 mrt 2026, 09:51 UTC

Belangrijke Marktbewegers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mrt 2026, 09:24 UTC

Belangrijke Marktbewegers

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1 jun 2026, 13:43 UTC

Marktinformatie

Roche Drug Candidate Will Have Role in Breast Cancer Treatment -- Market Talk

13 mei 2026, 10:20 UTC

Marktinformatie

Winsten

Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

7 mei 2026, 05:53 UTC

Acquisities, Fusies, Overnames

Correct: Roche to Buy PathAI for up to $1.05B

7 mei 2026, 05:07 UTC

Acquisities, Fusies, Overnames

Roche: Acquisition Expected to Complete in 2H

7 mei 2026, 05:06 UTC

Acquisities, Fusies, Overnames

Roche: Closing of Deal Subject to Customary Closing Conditions

7 mei 2026, 05:06 UTC

Acquisities, Fusies, Overnames

Roche to Pay $750M Upfront, Milestone Payments of Up to $300M

7 mei 2026, 05:06 UTC

Acquisities, Fusies, Overnames

Roche to Buy PathAI for up to $1.5B

7 mei 2026, 05:05 UTC

Acquisities, Fusies, Overnames

Roche to Buy PathAI

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

27 apr 2026, 09:54 UTC

Marktinformatie

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 apr 2026, 08:10 UTC

Marktinformatie

Winsten

Roche Reports In Line Sales Figures -- Market Talk

23 apr 2026, 05:04 UTC

Winsten

Roche Backs 2026 View

23 apr 2026, 05:04 UTC

Winsten

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 apr 2026, 05:03 UTC

Winsten

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 apr 2026, 05:02 UTC

Winsten

Roche 1Q Group Sales Up 6% at Constant Currency

23 apr 2026, 05:02 UTC

Winsten

Analysts Saw Roche 1Q Sales at CHF14.73B

23 apr 2026, 05:01 UTC

Winsten

Roche 1Q Sales CHF14.72B

10 apr 2026, 11:28 UTC

Marktinformatie

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 apr 2026, 11:17 UTC

Marktinformatie

Roche to Face Significant Currency Headwinds -- Market Talk

11 mrt 2026, 10:57 UTC

Marktinformatie

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mrt 2026, 09:43 UTC

Populaire aandelen

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mrt 2026, 07:22 UTC

Marktinformatie

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mrt 2026, 07:22 UTC

Marktinformatie

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

Peer Vergelijking

Prijswijziging

Roche Holding AG Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Roche Holding AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

17 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Andere aandelen uit de sector

NOVN.CH

Novartis AG

117.3

↓-0.46%

SOON.CH

Sonova Holding AG

204.4

↓-1.83%

Roche Holding AG

Overzicht

Wijziging aandelenprijs

Belangrijke statistieken

Dividenden

Marktinformatie

Nieuwssentiment

Roche Holding AG Grafiek

Gerelateerd nieuws

Peer Vergelijking

Roche Holding AG Prognose

Beoordelingsconsensus

Sentiment

Financieel

Over Roche Holding AG

Andere aandelen uit de sector